| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-77855SS | |||
| Azide and BSA Free | NBP2-80773 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB120-6405SS | |||
| Azide and BSA Free | NBP2-80848 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-77080SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-101SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB100-64775-0.05mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-47518SS | |||
| Azide and BSA Free | NBP2-80610 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-654SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-585SS | |||
| Azide and BSA Free | NBP2-80976 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-27416 | |||
| BSA Free | NB100-56712SS | |||
| Azide and BSA Free | NBP2-27416SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-92243SS | |||
![Dual RNAscope ISH-IHC: HLA-DR Antibody (L243) [NB100-77855] - Formalin-fixed paraffin-embedded tissue sections of human metastatic tonsil were probed for HLA-DR mRNA (ACD RNAScope probe, catalog # 475891; Fast Red chromogen, ACD catalog # 322500). Adjacent tissue section was processes for immunohistochemistry using mouse monoclonal (Novus catalog # NB100-77855) at 1:50 dilution for 1 hour at room temperature followed by incubation with the anti-mouse IgG VisUCyte HRP Polymer Antibody (Catalog # VC001) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue).](http://images.novusbio.com/fullsize/HLA-DR-Antibody-L243-Dual-RNAscope-ISH-IHC-NB100-77855-img0016.jpg "<b>Orthogonal Strategies Validation. </b>Dual RNAscope ISH-IHC: HLA-DR Antibody (L243) [NB100-77855] - Formalin-fixed paraffin-embedded tissue sections of human metastatic tonsil were probed for HLA-DR mRNA (ACD RNAScope probe, catalog # 475891; Fast Red chromogen, ACD catalog # 322500). Adjacent tissue section was processes for immunohistochemistry using mouse monoclonal (Novus catalog # NB100-77855) at 1:50 dilution for 1 hour at room temperature followed by incubation with the anti-mouse IgG VisUCyte HRP Polymer Antibody (Catalog # VC001) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue).")
![<b>Orthogonal Strategies Validation. </b>Western Blot: HLA-DR Antibody (L243) [NB100-77855] - Analysis of human spleen (A) and human tonsil (B) tissue using HLA-DR antibody at 2 ug/mL.](http://images.novusbio.com/fullsize/HLA-DR-Antibody-L243-Western-Blot-NB100-77855-img0002.jpg)
![Immunohistochemistry-Paraffin: HLA-DR Antibody (L243) [NB100-77855] - Staining of HLA-DR in human spleen using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/HLA-DR-Antibody-L243-Immunohistochemistry-Paraffin-NB100-77855-img0003.jpg)
![Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Analysis using the FITC conjugate of NB100-77855. Staining of Human peripheral blood lymphocytes with L243 FITC.](http://images.novusbio.com/fullsize/HLA-DR-Antibody-L243-Flow-Cytometry-NB100-77855-img0015.jpg)
![Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Human peripheral blood lymphocytes stained with L243 PE](http://images.novusbio.com/fullsize/HLA-DR-Antibody-L243-Flow-Cytometry-NB100-77855-img0001.jpg)
![Flow (Cell Surface): HLA-DR Antibody (L243) [NB100-77855] - Analysis using the Azide Free version of NB100-77855. Staining of HLA-DR expression by 5x10^5 BDCM cells using 0.5 ug of (red) and 0.5 ug of isotype control (green). This antibody and an anti-mouse IgG PE conjugated secondary antibody were used.](http://images.novusbio.com/fullsize/HLA-DR-Antibody-L243-Flow-Cell-Surface-NB100-77855-img0010.jpg)
![Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Analysis using the PerCP/Cy5.5 conjugate of NB100-77855. Staining of HLA-DR expression by 5x10^5 human PBMC using 10 uL (0.25 ug) of this antibody. Cell surface flow kit was used for this test. Left panel shows the monocyte gate, right panel shows the lymphocyte gate.](http://images.novusbio.com/fullsize/HLA-DR-Antibody-L243-Flow-Cytometry-NB100-77855-img0011.jpg)
![Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Analysis using the Alexa Fluor (R) 700 conjugate of NB100-77855. Staining of HLA-DR protein in human PBMCs using HLA-DR antibody [clone L243; conjugated to Alexa Fluor (R) 700] at 1:100 with 25 minutes incubation at 4C in 2% human serum, 0.5 mM EDTA in DPBS. Image from verified customer review.](http://images.novusbio.com/fullsize/HLA-DR-Antibody-L243-Flow-Cytometry-NB100-77855-img0012.jpg)
![Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Analysis using the Biotin conjugate of NB100-77855. Staining of Human peripheral blood lymphocytes with biotinylated L243, followed by Sav-PE.](http://images.novusbio.com/fullsize/HLA-DR-Antibody-L243-Flow-Cytometry-NB100-77855-img0013.jpg)
![Flow Cytometry: HLA-DR Antibody (L243) [NB100-77855] - Analysis using the DyLight 405 conjugate of NB100-77855. Staining of HLA-DR in human PBMCs using anti-HLA-DR antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/HLA-DR-Antibody-L243-Flow-Cytometry-NB100-77855-img0014.jpg)
![Immunocytochemistry/Immunofluorescence: MHC Class I Antibody (OX18) [NB120-6405] - Major histocompatibility complex (MHC) I and II as well as Transporter associated with antigen presentation II (TAPII) were analyzed, using immunocytochemistry on rat Schwann cells (SCs). Corresponding merges are shown in the bottom rows. Treatment of SCs with IL-17 was performed at concentrations of 0.5 and 50 ng/mL. Graphs to the right show densitometry quantification. SCs showed expression of MHCI > TAPII > MHCII, which increased after IL-17 treatment. MHCI was mainly detected in the cytoplasm and the expression increased in a dose-dependent manner after IL-17 treatment, significant for 0.5 ng/mL and 50 ng/mL (**P TAPII > MHCII, which increased after IL-17 treatment. (A) MHCI was mainly detected in the cytoplasm and the expression increased in a dose-dependent manner after IL-17 treatment, significant for 0.5 ng/mL and 50 ng/mL (**P ≤0.01). (B) MHCII revealed a fainter basic expression emphasizing the nucleus and was found significantly increased after 0.5 ng/mL IL-17 stimulation (**P ≤ 0.01). (C) TAPII was detected in the nucleus and cytoplasm. We detected a dose-dependent tendency but no significantly increased expression after IL-17 stimulation. For MHCI, TAPII and MHCII and the concentrations applied, analysis of variance between the independent experiments revealed no significant difference. DAPI, 4′, 6-diamidino-2-phenylindole. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/24678820), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-85960_rabbit-polyclonal-sfxn2-antibody-western-blot-13220261739815.jpg "Immunocytochemistry/Immunofluorescence: MHC Class I Antibody (OX18) [NB120-6405] - Major histocompatibility complex (MHC) I and II as well as Transporter associated with antigen presentation II (TAPII) were analyzed, using immunocytochemistry on rat Schwann cells (SCs). Corresponding merges are shown in the bottom rows. Treatment of SCs with IL-17 was performed at concentrations of 0.5 and 50 ng/mL. Graphs to the right show densitometry quantification. SCs showed expression of MHCI > TAPII > MHCII, which increased after IL-17 treatment. MHCI was mainly detected in the cytoplasm and the expression increased in a dose-dependent manner after IL-17 treatment, significant for 0.5 ng/mL and 50 ng/mL (**P TAPII > MHCII, which increased after IL-17 treatment. (A) MHCI was mainly detected in the cytoplasm and the expression increased in a dose-dependent manner after IL-17 treatment, significant for 0.5 ng/mL and 50 ng/mL (**P ≤0.01). (B) MHCII revealed a fainter basic expression emphasizing the nucleus and was found significantly increased after 0.5 ng/mL IL-17 stimulation (**P ≤ 0.01). (C) TAPII was detected in the nucleus and cytoplasm. We detected a dose-dependent tendency but no significantly increased expression after IL-17 stimulation. For MHCI, TAPII and MHCII and the concentrations applied, analysis of variance between the independent experiments revealed no significant difference. DAPI, 4′, 6-diamidino-2-phenylindole. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/24678820), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 promoted the activation of canonical NLRP3 inflammasome in retinal IR injury. The intravitreal injection of HMGB1 inhibitor, GA, significantly suppressed mRNA (B) and protein (D) production of NLRP3. Data are shown as mean +/- SD. **P < 0.01 vs sham group. Image collected and cropped by CiteAb from the following publication (//www.jneuroinflammation.com/content/12/1/137) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Western-Blot-NBP1-77080-img0011.jpg "Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 promoted the activation of canonical NLRP3 inflammasome in retinal IR injury. The intravitreal injection of HMGB1 inhibitor, GA, significantly suppressed mRNA (B) and protein (D) production of NLRP3. Data are shown as mean +/- SD. **P < 0.01 vs sham group. Image collected and cropped by CiteAb from the following publication (//www.jneuroinflammation.com/content/12/1/137) licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Staining of NALP3 in K562 cells with NALP3 antibody at 2 ug/mL.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NBP1-77080-img0010.jpg)
![Immunohistochemistry-Paraffin: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Analysis of NALP3 in mouse lung tissue using anti-NALP3 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Immunohistochemistry-Paraffin-NBP1-77080-img0003.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Analysis of NALP3 in K562 cell lysate with NALP3 antibody at 1 ug/mL (A) in the absence and (B) in the presence of blocking peptide.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Western-Blot-NBP1-77080-img0009.jpg)
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - hADSC-Evs suppressed NLRP3 inflammasome activation in ocular surface of experimental mice under desiccating stress. Representative image of immunofluorescent staining of NLRP3 related genes in corneal and conjunctival epithelia of desiccating mice or treated with hADSC-EVs (*conjunctiva; open triangle cornea). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32884023/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NLRP3-NALP3 Antibody - BSA Free-Immunocytochemistry-Immunofluorescence-NBP1-77080-img0012.jpg)
![Immunocytochemistry/ Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - hADSC-Evs suppressed NLRP3 inflammasome activation in ocular surface of experimental mice under desiccating stress. (A) Representative image of immunofluorescent staining of NLRP3 related genes in corneal & conjunctival epithelia of desiccating mice or treated with hADSC-EVs (*conjunctiva; open triangle cornea). (B,C) qRT-PCR showed the mRNA levels of NLRP3 related genes in conjunctiva & cornea (four corneas/conjunctivas were mixed as a sample). Data was shown as mean ± SEM. *p < 0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32884023), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-31020241535675.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 promoted the activation of canonical NLRP3 inflammasome in retinal IR injury. The intravitreal injection of exogenous rHMGB1 significantly promoted the mRNA & protein production of NLRP3 (a, c) & ASC (e, g) & activation of caspase-1 (i). Thus, the intravitreal injection of HMGB1 inhibitor, GA, significantly suppressed the production of NLRP3 (b, d) & ASC (f, h) & activation of caspase-1 (j). Data are shown as mean ± SD. *P < 0.05, **P < 0.01 vs sham group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26224068), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-310202415345338.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Co-immunoprecipitation assay: Figure showing interaction of NLRP3, NLRC4 & NAIP with ASC during CFT073 infection in THP-1m. Cytoplasmic extracts of THP-1m infected with or without CFT073, 6 h post stimulation were subjected to IP & WB by various antibodies (ASC, NLRP3, NLRC4, & NAIP) as described in material & methods. Cytoplasmic extract used as input was subjected to check NLRP3, ASC, NLRC4 & NAIP expression as shown in figure. ASC antibody was used to co-immunoprecipitate the complex from cytoplasmic extracts & then immunoblotted to detect NLRP3, NLRC4 & NAIP. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31551961), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-310202415371971.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 regulated the activation of NLRP3, rather than the activation of caspase-8, via NF-kappa B pathway. a, b NF-kappa B was activated in ischemic retina at the early stage after reperfusion. c, d Intraocular injection rHMGB1 or GA could promote or suppress the production of phosphor-NF-kappa B p65. e, f Intravitreal injection of NF-kappa B p65 inhibitor, JSH-23, significantly reduced the activation of NLRP3 & decreased the processing of IL-1 beta , g rather than caspase-8. However, intravitreal injection of caspase-8 inhibitor, Z-IETD-fmk, decreased the production of phosphor-NF-kappa B p65, obviously (h). Data are shown as mean ± SD. *P < 0.05, **P < 0.01 vs sham group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26224068), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-310202415291993.jpg)
![Western Blot: Calreticulin Antibody [NB600-101] - Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and Calreticulin knockout (KO) HeLa cell line. PVDF membrane was probed with 1:1500 of Rabbit Anti-Human Calreticulin Polyclonal Antibody (Catalog # NB600-101) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog #HAF008). Specific band was detected for Calreticulin at approximately 55 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-Knockdown-Validated-NB600-101-img0011.jpg "<b>Genetic Strategies Validation. </b>Western Blot: Calreticulin Antibody [NB600-101] - Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and Calreticulin knockout (KO) HeLa cell line. PVDF membrane was probed with 1:1500 of Rabbit Anti-Human Calreticulin Polyclonal Antibody (Catalog # NB600-101) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog #HAF008). Specific band was detected for Calreticulin at approximately 55 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.")
![<b>Genetic Strategies Validation. </b>Western Blot: Calreticulin Antibody [NB600-101] - Human kidney lysate.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-Western-Blot-NB600-101-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: Calreticulin Antibody [NB600-101] - Immunofluorescence staining of Calreticulin in HCT15 colon cancer cells using NB600-101. Secondary antibody was conjugated with Alexa Fluor 488. Photo courtesy of Dr. Birkenkamp Demtroeder, Arhus University Hospital.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-Immunocytochemistry-Immunofluorescence-NB600-101-img0005.jpg)
![Immunohistochemistry-Paraffin: Calreticulin Antibody [NB600-101] - Analysis of a FFPE tissue section of human thyroid gland using 1:50 dilution of Calreticulin antibody. The signal was developed using HRP-DAB based detection method which followed counterstaining of the nuclei with hematoxylin. This representative section shows a strong positivity of Calreticulin in the follicular epithelial cells, wherein the signal was found to be very intense in the perinuclear region of the cells which correlates well with Endoplasmic reticulum localization of this protein. The para-follicular cells, endothelial cells of blood vessels (not the RBCs though) and the loose connective tissue in the section showed a weak cytoplasmic staining. Some staining was observed in the follicles/colloids also which is potentially the secreted form of Calreticulin.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-Immunohistochemistry-Paraffin-NB600-101-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: Calreticulin Antibody [NB600-101] - The Calreticulin antibody NB600-101 was tested in HeLa cells at a 1:250 dilution against DyLight 488 (Green). Alpha-tubulin and nuclei were counterstained against DyLight 550 (Red) and DAPI (Blue), respectively.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-Immunocytochemistry-Immunofluorescence-NB600-101-img0007.jpg)
![Immunohistochemistry-Paraffin: Calreticulin Antibody [NB600-101] - Analysis of a FFPE tissue section of human thyroid gland using 1:50 dilution of Calreticulin antibody. The signal was developed using HRP-DAB based detection method which followed counterstaining of the nuclei with hematoxylin. This representative section shows a strong positivity of Calreticulin in the follicular epithelial cells, wherein the signal was found to be very intense in the perinuclear region of the cells which correlates well with Endoplasmic reticulum localization of this protein. The para-follicular cells, endothelial cells and the loose connective tissue in the section showed a weak cytoplasmic staining. Some staining was observed in the follicles/colloids also which is potentially the secreted form of Calreticulin.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-Immunohistochemistry-Paraffin-NB600-101-img0009.jpg)
![Simple Western: Calreticulin Antibody [NB600-101] - Lane view shows a specific band for Calreticulin in 0.5 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-Simple-Western-NB600-101-img0008.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - BDNF lowered the mechanical withdrawal threshold further and promoted activation of astrocytes and microglia, and enhanced the p38/JNK pathway to aggravate the release of IL-1beta and TNF-alpha in the SDH of CYP-induced cystitis. Western blots showing the expression of BDNF was further upregulated when compared with the CYP + PBS group. Data of mechanical withdrawal threshold were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean +/- SEM (n = 10 per group). **p < 0.01, ***p < 0.001 vs. the control group. #p < 0.05, ##p < 0.01, ###p < 0.001 vs. the CYP + rBDNF group. $p < 0.05, $$p < 0.01, $$$p < 0.001 vs. the CYP + PBS group.](http://images.novusbio.com/fullsize/BDNF-Antibody-Western-Blot-NB100-98682-img0010.jpg "<b>Biological Strategies Validation. </b>Western Blot: BDNF Antibody [NB100-98682] - BDNF lowered the mechanical withdrawal threshold further and promoted activation of astrocytes and microglia, and enhanced the p38/JNK pathway to aggravate the release of IL-1beta and TNF-alpha in the SDH of CYP-induced cystitis. Western blots showing the expression of BDNF was further upregulated when compared with the CYP + PBS group. Data of mechanical withdrawal threshold were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean +/- SEM (n = 10 per group). **p < 0.01, ***p < 0.001 vs. the control group. #p < 0.05, ##p < 0.01, ###p < 0.001 vs. the CYP + rBDNF group. $p < 0.05, $$p < 0.01, $$$p < 0.001 vs. the CYP + PBS group.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry: BDNF Antibody [NB100-98682] - Effects of mBMSC and EA treatment on the expression of mBDNF and NT4 in neurons. Photomicrographs for mBDNF/NeuN or NT4/NeuN double-positive cells in the striatum and hippocampus (n = 5). The number of mBDNF/NeuN double-positive cells in the SVZ + striatum and hippocampus was significantly higher in the EA-treated MCAO group and the combined mBMSC + EA-treated MCAO group, compared to the number in the other groups. The number of NT4/NeuN double-positive cells in the hippocampus was significantly higher in the EA-treated MCAO group than in the vehicle-treated MCAO group. #p < 0.05 and ##p < 0.01 versus control group; *p < 0.05, **p < 0.01, and ***p < 0.001 versus vehicle-treated MCAO group; &&p < 0.01 versus mBMSC-treated MCAO group. Scale bar = 100 um. Image collected and cropped by CiteAb from the following publication (www.nature.com/articles/s41598-018-20481-3) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/BDNF-Antibody-Immunohistochemistry-NB100-98682-img0007.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - Human platelet lysate and recombinant mature BDNF. Blocking: 1% LFDM for 30 min at RT; primary antibody (1:1000) incubated at 4C overnight.](http://images.novusbio.com/fullsize/BDNF-Antibody-Western-Blot-NB100-98682-img0006.jpg)
![Immunohistochemistry-Paraffin: BDNF Antibody [NB100-98682] - Mouse hippocampus. The animal was perfused at a pressure of 130 mmHg with 300 ml 4% FA before being processed for paraffin embedding. HIER: Tris-EDTA, pH 9 for 20 min. Blocking: 0.2% LFDM in TBST filtered thru 0.2 um. Detection was done using Novolink HRP polymer from Leica following manufacturers instructions; DAB chromogen: Candela DAB chromogen. Primary antibody: dilution 1: 1000, incubated 30 min at RT. Sections were counterstained with Harris Hematoxylin.](http://images.novusbio.com/fullsize/BDNF-Antibody-Immunohistochemistry-Paraffin-NB100-98682-img0001.jpg)
![Immunohistochemistry-Paraffin: BDNF Antibody [NB100-98682] - Mouse hippocampus. The animal was perfused at a pressure of 130 mmHg with 300 ml 4% FA before being processed for paraffin embedding. HIER: Tris-EDTA, pH 9 for 20 min. Blocking: 0.2% LFDM in TBST filtered thru 0.2 um. Detection was done using Novolink HRP polymer from Leica following manufacturers instructions; DAB chromogen: Candela DAB chromogen. Primary antibody: dilution 1: 1000, incubated 30 min at RT. Sections were counterstained with Harris Hematoxylin.](http://images.novusbio.com/fullsize/BDNF-Antibody-Immunohistochemistry-Paraffin-NB100-98682-img0003.jpg)
![Immunohistochemistry-Paraffin: BDNF Antibody [NB100-98682] - Mouse hippocampus. The animal was perfused at a pressure of 130 mmHg with 300 ml 4% FA before being processed for paraffin embedding. HIER: Tris-EDTA, pH 9 for 20 min. Blocking: 0.2% LFDM in TBST filtered thru 0.2 um. Detection was done using Novolink HRP polymer from Leica following manufacturers instructions; DAB chromogen: Candela DAB chromogen. Primary antibody: dilution 1: 1000, incubated 30 min at RT. Sections were counterstained with Harris Hematoxylin.](http://images.novusbio.com/fullsize/BDNF-Antibody-Immunohistochemistry-Paraffin-NB100-98682-img0005.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - Effect of treatment with FX extract on CREB/BDNF signaling. (a-c) Differences in the phosphorylation of CREB & expression of BDNF between groups in the PFC & hippocampus (n = 3-4). (d, e) pCREB & BDNF immunofluorescence was assessed in the PFC & hippocampus (n = 3-4). Mean ± SD. #P < 0.05 versus normal group; ∗P < 0.05 & ∗∗P < 0.01 versus control group. Scale bar = 200 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30065945), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202415371951.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - Effect of treatment with FX extract on CREB/BDNF signaling. (a-c) Differences in the phosphorylation of CREB & expression of BDNF between groups in the PFC & hippocampus (n = 3-4). (d, e) pCREB & BDNF immunofluorescence was assessed in the PFC & hippocampus (n = 3-4). Mean ± SD. #P < 0.05 versus normal group; ∗P < 0.05 & ∗∗P < 0.01 versus control group. Scale bar = 200 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30065945), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202415175223.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - Antagonized TrkB could restrain the activation of astrocytes & microglia & supress the p38/JNK pathway to alleviate the release of IL-1 beta & TNF-alpha in the SDH of CYP-induced cystitis. Western blots showed that the overexpression of a BDNF, b TrkB, cp-TrkB, d Iba1, e GFAP, fp-p38, gp-JNK, h TNF-alpha , & i IL-1 beta were downregulated in comparison to the CYP + DMSO group after ANA-12 treatment. All data were calculated as mean ± SEM (n = 5 per group). **p < 0.01, ***p < 0.001 vs. control group. ##p < 0.01, ###p < 0.001 vs. CYP + ANA-12 group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31931832), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202415291934.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - BDNF lowered the mechanical withdrawal threshold further & promoted activation of astrocytes & microglia, & enhanced the p38/JNK pathway to aggravate the release of IL-1 beta & TNF-alpha in the SDH of CYP-induced cystitis. a BDNF treated every other day after CYP injection could further lower the mechanical withdrawal threshold & suppress the retrieval of mechanical threshold when compared with the CYP + PBS group. After the exogenous BDNF injection, Western blots showing the expression of b BDNF, c TrkB, dp-TrkB, e Iba1, f GFAP, gp-p38, hp-JNK, i TNF-alpha , & j IL-1 beta were all further upregulated when compared with the CYP + PBS group. Data of mechanical withdrawal threshold were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean ± SEM (n = 10 per group). **p < 0.01, ***p < 0.001 vs. the control group. #p < 0.05, ##p < 0.01, ###p < 0.001 vs. the CYP + rBDNF group. $p < 0.05, $$p < 0.01, $$$p < 0.001 vs. the CYP + PBS group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31931832), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202416284921.jpg)
![Immunohistochemistry: BDNF Antibody [NB100-98682] - Effects of mBMSC & EA treatment on the expression of trophic factors. (A) Photomicrographs & (B‒D) histograms for mBDNF, NT4, & VEGF expression (n = 4–5). mBDNF expression was markedly increased by treatment with mBMSC and/or EA compared to vehicle treatment. mBDNF expression levels were higher in the EA-treated MCAO group than in the mBMSC-treated MCAO group. NT4 expression in the SVZ & hippocampus was significantly higher in the combined mBMSC & EA treatment group than in the other groups. VEGF expression in the hippocampus was markedly higher in the mBMSC treatment group than in the vehicle-treated MCAO group. #p < 0.05, ##p < 0.01, & ###p < 0.001 versus control group; *p < 0.05, **p < 0.01, & ***p < 0.001 versus vehicle-treated MCAO group; &p < 0.05, &&p < 0.01, & &&&p < 0.001 versus mBMSC-treated MCAO group; Scale bar = 1 mm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29391466), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202416284912.jpg)
![Western Blot: BDNF Antibody [NB100-98682] - The expression of BDNF-TrkB signaling in the SDH of CYP-induced cystitis. a Changes of the mechanical threshold in CYP-induced cystitis model. Compared to that in the control group, the mechanical threshold of the cystitis group decreased significantly after the CYP injection & remained low until day 17, & the minimum threshold value was reached on day 12. The expression of b BDNF, c TrkB, & dp-TrkB were evaluated by western blots. Compared to the control group, they were upregulated on days 8, 12, & 17. e Immunofluorescence double staining assay of BDNF & p-TrkB in the SDH. BDNF & p-TrkB (red), NeuN, GFAP, & OX-42( green), co-localization (yellow). BDNF was mainly colocalized in neurons which mainly located in Laminate II to IV. & TrkB receptors expressed in neurons, microglia, & astrocytes. The white dotted lines in picture “BDNF/NeuN” showed the laminate of the SDH according to Rexed & Steiner. Scale bar = 100 μm. All data were calculated as mean ± SEM (n = 5 per group). *p < 0.05, ** p < 0.01, *** p < 0.001 vs. the control group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31931832), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-98682_rabbit-polyclonal-bdnf-antibody-310202416284910.jpg)
![Immunohistochemistry-Frozen: HLA ABC Antibody (W6/32) [NB100-64775] - Analysis of Mouse colon cancer tissue using HLA ABC antibody (W6/32). Primary antibody dilution was 1:100. Sample was incubated with secondary antibody in 1:300 dilution. Image from verified customer review.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Immunohistochemistry-Frozen-NB100-64775-img0015.jpg "Immunohistochemistry-Frozen: HLA ABC Antibody (W6/32) [NB100-64775] - Analysis of Mouse colon cancer tissue using HLA ABC antibody (W6/32). Primary antibody dilution was 1:100. Sample was incubated with secondary antibody in 1:300 dilution. Image from verified customer review.")
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Analysis using the FITC conjugate of NB100-64775. Staining of normal human peripheral blood cells with Mouse IgG2a K Isotype Control FITC (NBP1-43955) (blue histogram) or Anti-Human HLA-ABC FITC (purple histogram). Cells in the lymphocyte gate were used f](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0013.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Staining of human peripheral blood lymphocytes with Mouse anti Human HLA ABC.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0002.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Staining of human peripheral blood lymphocytes with Mouse anti Human HLA ABC:Alexa Fluor 488.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0004.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Staining of human peripheral blood lymphocytes with Mouse anti Human HLA ABC:Alexa Fluor 647.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0006.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Staining of human peripheral blood lymphocytes with Mouse anti Human HLA ABC:FITC.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0007.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Staining of human peripheral blood monocytes with Mouse anti Human HLA ABC:Biotin.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0008.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Human lymphoblast. Image provided via verified customer review.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0009.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Staining of peripheral blood lymphocytes with anti-HLA-ABC: Low Endotoxin.](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0010.jpg)
![Flow Cytometry: HLA ABC Antibody (W6/32) [NB100-64775] - Analysis using the PE/Cy5 conjugate of NB100-64775. Staining of normal human peripheral blood cells with Mouse IgG2a K Isotype Control PE-Cy5 (NBP1-43073) (blue histogram) or Anti-Human HLA-ABC PE-Cy5 (purple histogram). Cells in the lymphocyte gate were](http://images.novusbio.com/fullsize/HLA-ABC-Antibody-W6-32-Flow-Cytometry-NB100-64775-img0014.jpg)
![Western Blot: Calreticulin Antibody (1G6A7) [NBP1-47518] - Analysis of whole cell lysates from HeLa, A549, NTERA2 and MCF-7 using Calreticulin antibody clone 1G6A7. The antibody generated a specific band of Calreticulin protein at ~48 kDa molecular weight position.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Western-Blot-NBP1-47518-img0017.jpg "Western Blot: Calreticulin Antibody (1G6A7) [NBP1-47518] - Analysis of whole cell lysates from HeLa, A549, NTERA2 and MCF-7 using Calreticulin antibody clone 1G6A7. The antibody generated a specific band of Calreticulin protein at ~48 kDa molecular weight position.")
![Flow (Intracellular): Calreticulin Antibody (1G6A7) [NBP1-47518] - Intracellular staining of 1 x 10^6 CHO (A) and HEK-293 (B) cells using Calreticulin antibody (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1x10^6 cells was used.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Flow-Cytometry-NBP1-47518-img0016.jpg)
![Immunocytochemistry/Immunofluorescence: Calreticulin Antibody (1G6A7) [NBP1-47518] - Antibody was tested in HeLa cells at a 1:250 against DyLight 488 (Green). Actin was counterstained against Phalloidin 568 (Red) and cells were mounted in DAPI Flouromount (Blue).](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Immunocytochemistry-Immunofluorescence-NBP1-47518-img0008.jpg)
![Western Blot: Calreticulin Antibody (1G6A7) [NBP1-47518] - Analysis using Calreticulin mouse mAb against HEK293T cells transfected with the pCMV6-ENTRY control (1) and pCMV6-ENTRY Calreticulin cDNA (2).](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Western-Blot-NBP1-47518-img0005.jpg)
![Immunohistochemistry-Paraffin: Calreticulin Antibody (1G6A7) [NBP1-47518] - Analysis of paraffin-embedded human placenta tissues using anti-Calreticulin mAb.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Immunohistochemistry-Paraffin-NBP1-47518-img0002.jpg)
![Flow Cytometry: Calreticulin Antibody (1G6A7) [NBP1-47518] - An intracellular stain was performed on A431 cells with Calreticulin (1G6A7) Antibody NBP1-47518 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 488.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Flow-Cytometry-NBP1-47518-img0038.jpg)
![Immunocytochemistry/Immunofluorescence: Calreticulin Antibody (1G6A7) [NBP1-47518] - Analysis of 3T3-L1 cells using anti-Calreticulin mAb (green). DRAQ5 fluorescent DNA dye (blue).](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Immunocytochemistry-Immunofluorescence-NBP1-47518-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: Calreticulin Antibody (1G6A7) [NBP1-47518] - Analysis of SKBR-3 (left) and A549 (right) cells using anti-Calreticulin mAb (green). Actin filaments have been labeled with DY-554 phalloidin (red). DRAQ5 fluorescent DNA dye (blue).](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Immunocytochemistry-Immunofluorescence-NBP1-47518-img0007.jpg)
![Flow (Intracellular): Calreticulin Antibody (1G6A7) [NBP1-47518] - A549 cells stained with NBP1-47518PCP (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to PerCP.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Flow-Cytometry-NBP1-47518-img0026.jpg)
![Flow (Intracellular): Calreticulin Antibody (1G6A7) [NBP1-47518] - U-937 cells stained with NBP1-47518F (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to FITC.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Flow-Cytometry-NBP1-47518-img0027.jpg)
![Flow (Intracellular): Calreticulin Antibody (1G6A7) [NBP1-47518] - Jurkat cells stained with NBP1-47518APC (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to allophycocyanin.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Flow-Cytometry-NBP1-47518-img0028.jpg)
![Flow Cytometry: Calreticulin Antibody (1G6A7) [NBP1-47518] - An intracellular stain was performed on HeLa cells with Calreticulin Antibody [1G6A7] NBP1-47518AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Flow-Cytometry-NBP1-47518-img0034.jpg)
![Western Blot: HIF-1 alpha Antibody [NB100-654] - Effects of in vitro hypoxia on the expression of mouse HIF-1 alpha in HIF-1 alpha+/- and HIF-1 alpha+/+ astrocytes. Confluent astrocyte monolayers of both cell types were exposed to a 6 h in vitro hypoxia. HIF-1 alpha mRNA expression was determined by RT-PCR as described in Materials and Methods. Each bar represents the mean +/- SD of relative density/volumes of the bands on film negatives from at least three experiments. Asterisks and number sign indicate significant difference (p < 0.01; one-way ANOVA, followed by multiple comparisons among means). Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-4-12), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Western-Blot-NB100-654-img0009.jpg "<b>Biological Strategies Validation, Genetic Strategies Validation and Orthogonal Strategies Validation.</b>Western Blot: HIF-1 alpha Antibody [NB100-654] - Effects of in vitro hypoxia on the expression of mouse HIF-1 alpha in HIF-1 alpha+/- and HIF-1 alpha+/+ astrocytes. Confluent astrocyte monolayers of both cell types were exposed to a 6 h in vitro hypoxia. HIF-1 alpha mRNA expression was determined by RT-PCR as described in Materials and Methods. Each bar represents the mean +/- SD of relative density/volumes of the bands on film negatives from at least three experiments. Asterisks and number sign indicate significant difference (p < 0.01; one-way ANOVA, followed by multiple comparisons among means). Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-4-12), licensed under a CC-BY license.")
![<b>Biological Strategies Validation, Genetic Strategies Validation and Orthogonal Strategies Validation.</b>Western Blot: HIF-1 alpha Antibody [NB100-654] - Effects of CoCl2 treatment on HIF-1 alpha expression in mouse astrocytes. Western blots using nuclear proteins show that both hypoxia (H) and CoCl2 (Co) up-regulated HIF-1 alpha protein in HIF-1 alpha+/+ and HIF-1 alpha+/- cells. There was no HIF-1 alpha protein detected in control cells. Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-4-12), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Western-Blot-NB100-654-img0008.jpg)
![Immunohistochemistry-Paraffin: HIF-1 alpha Antibody [NB100-654] - IHC analysis of a formalin-fixed paraffin-embedded tissue section of human endometrium carcinoma AN3CA cell line based xenograft using rabbit polyclonal HIF-1 alpha antibody NB100-654 at 1:300 dilution. The signal was developed using HRP-labelled secondary antibody and DAB reagent, and the section was further counterstained using hematoxylin. The tested section depicted mainly a diffused cytoplasmic staining but there were some cells which showed nuclear signal also (representing hypoxic cells).](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Immunohistochemistry-Paraffin-NB100-654-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody [NB100-654] - HIF1-alpha analysis using NB100-654. Image submitted from verified customer review.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Western-Blot-NB100-654-img0007.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody [NB100-654] - Detection of HIF-1 alpha in cobalt chloride treated/untreated COS-7 nuclear extracts using NB100-654.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Western-Blot-NB100-654-img0003.jpg)
![Simple Western: HIF-1 alpha Antibody [NB100-654] - Simple Western lane view shows a specific band for HIF-1 alpha in 0.5 mg/ml of Hypoxic HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Simple-Western-NB100-654-img0005.jpg)
![Gel Super Shift Assays: HIF-1 alpha Antibody [NB100-654] - Mouse HIF-1 alpha+/+ and HIF-1 alpha+/- cells were exposed to hypoxia or 125 uM CoCl2 for 6 h, nuclear extracts were then prepared and EMSA carried out. HIF-1 isolated from hypoxia or CoCl2-treated cells bound to the wild-type probe (lanes #1-6) but not to the mutant probe (lanes #7-12). HIF-1/DNA complex was detected in hypoxia (H)-or CoCl2 (Co)-treated cells (lanes #2, 3, 5, 6) but not in control (C) cells (lanes #1, 4). More complex (darker band) was seen in hypoxia-or CoCl2-treated HIF-1 alpha+/+ cells (lanes #2, 3) than that in hypoxia-or CoCl2-treated HIF-1 alpha+/- cells (lanes #5, 6). Supershift assay showed that the HIF-1/DNA complex was shifted up in the presence of wild-type (wt) oligo probe and 4 ug HIF-1 alpha antiboby (lanes #13 & 14). Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-4-12), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Gel-Super-Shift-Assays-NB100-654-img0011.jpg)
![Western Blot: HIF-1 alpha Antibody - BSA Free [NB100-654] - Effects of CoCl2 treatment on HIF-1 alpha expression in mouse astrocytes. (A) The cells were incubated in the presence or absence of 125 μM CoCl2 for 6 hr. HIF-1 alpha mRNA expression was determined by RT-PCR. Each bar represents the mean ± SD of relative density/volumes of the bands on film negatives from at least three experiments. Asterisk & number sign indicate significant difference compared to relevant controls (p < 0.01; one-way ANOVA, followed by multiple comparisons among means). (B) Western blots using nuclear proteins show that both hypoxia (H) & CoCl2 (Co) up-regulated HIF-1 alpha protein in HIF-1 alpha +/+ & HIF-1 alpha +/- cells. There was no HIF-1 alpha protein detected in control cells (C). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17474992), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-654_rabbit-polyclonal-hif-1-alpha-antibody-31020241529191.jpg)
![Western Blot: HIF-1 alpha Antibody - BSA Free [NB100-654] - Aberrant HIF1 alpha expression in PDAC cancer associated fibroblastsA. The level of MCT4 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. B. The level of MCT1 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. C. HIF alpha & MCT4 levels were determined by immunoblotting following the knockdown of HIF1 alpha with RNAi or the induction of hypoxia through the use of CoCl2. D. The stability of HIF1 alpha was evaluated in CAFs following treatment with cycloheximide. E. HIF1 alpha was detected by immunoblotting in the presence of cycloheximide in the absence or presence of the proteasome inhibitor MG132. F. HIF1 alpha protein levels were determined in the absence & presence of DMOG. G. RNA levels of the indicated genes as determined by microarray analyses (**p < 0.01 for tumor cell line vs. CAF). H. MG132 was used to interrogate the synthetic rate of HIF1 alpha protein in the indicated cell lines. I. The expression of HIF1 alpha target genes was evaluated in the indicated cell lines by microarray analysis (**p < 0.01 for tumor cell vs. CAF). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27623078), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-654_rabbit-polyclonal-hif-1-alpha-antibody-31020241553714.jpg)
![Western Blot: HIF-1 alpha Antibody - BSA Free [NB100-654] - Aberrant HIF1 alpha expression in PDAC cancer associated fibroblastsA. The level of MCT4 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. B. The level of MCT1 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. C. HIF alpha & MCT4 levels were determined by immunoblotting following the knockdown of HIF1 alpha with RNAi or the induction of hypoxia through the use of CoCl2. D. The stability of HIF1 alpha was evaluated in CAFs following treatment with cycloheximide. E. HIF1 alpha was detected by immunoblotting in the presence of cycloheximide in the absence or presence of the proteasome inhibitor MG132. F. HIF1 alpha protein levels were determined in the absence & presence of DMOG. G. RNA levels of the indicated genes as determined by microarray analyses (**p < 0.01 for tumor cell line vs. CAF). H. MG132 was used to interrogate the synthetic rate of HIF1 alpha protein in the indicated cell lines. I. The expression of HIF1 alpha target genes was evaluated in the indicated cell lines by microarray analysis (**p < 0.01 for tumor cell vs. CAF). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27623078), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-654_rabbit-polyclonal-hif-1-alpha-antibody-31020241682154.jpg)
![Western Blot: HIF-1 alpha Antibody - BSA Free [NB100-654] - Aberrant HIF1 alpha expression in PDAC cancer associated fibroblastsA. The level of MCT4 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. B. The level of MCT1 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. C. HIF alpha & MCT4 levels were determined by immunoblotting following the knockdown of HIF1 alpha with RNAi or the induction of hypoxia through the use of CoCl2. D. The stability of HIF1 alpha was evaluated in CAFs following treatment with cycloheximide. E. HIF1 alpha was detected by immunoblotting in the presence of cycloheximide in the absence or presence of the proteasome inhibitor MG132. F. HIF1 alpha protein levels were determined in the absence & presence of DMOG. G. RNA levels of the indicated genes as determined by microarray analyses (**p < 0.01 for tumor cell line vs. CAF). H. MG132 was used to interrogate the synthetic rate of HIF1 alpha protein in the indicated cell lines. I. The expression of HIF1 alpha target genes was evaluated in the indicated cell lines by microarray analysis (**p < 0.01 for tumor cell vs. CAF). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27623078), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-654_rabbit-polyclonal-hif-1-alpha-antibody-310202415523946.jpg)
![Western Blot: HIF-1 alpha Antibody - BSA Free [NB100-654] - Aberrant HIF1 alpha expression in PDAC cancer associated fibroblastsA. The level of MCT4 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. B. The level of MCT1 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. C. HIF alpha & MCT4 levels were determined by immunoblotting following the knockdown of HIF1 alpha with RNAi or the induction of hypoxia through the use of CoCl2. D. The stability of HIF1 alpha was evaluated in CAFs following treatment with cycloheximide. E. HIF1 alpha was detected by immunoblotting in the presence of cycloheximide in the absence or presence of the proteasome inhibitor MG132. F. HIF1 alpha protein levels were determined in the absence & presence of DMOG. G. RNA levels of the indicated genes as determined by microarray analyses (**p < 0.01 for tumor cell line vs. CAF). H. MG132 was used to interrogate the synthetic rate of HIF1 alpha protein in the indicated cell lines. I. The expression of HIF1 alpha target genes was evaluated in the indicated cell lines by microarray analysis (**p < 0.01 for tumor cell vs. CAF). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27623078), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-654_rabbit-polyclonal-hif-1-alpha-antibody-31020241553515.jpg)
![Western Blot: TfR (Transferrin R) Antibody (OX26) [NB200-585] - Total protein from rat adrenal gland cells (PC12) and rat placenta was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2 ug/ml anti-CD71 in 1% milk, and detected with an anti-mouse HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/TfR-Transferrin-R-Antibody-OX26-Western-Blot-NB200-585-img0009.jpg "Western Blot: TfR (Transferrin R) Antibody (OX26) [NB200-585] - Total protein from rat adrenal gland cells (PC12) and rat placenta was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2 ug/ml anti-CD71 in 1% milk, and detected with an anti-mouse HRP secondary antibody using chemiluminescence.")
![Immunocytochemistry/Immunofluorescence: TfR (Transferrin R) Antibody (OX26) [NB200-585] - PC-12 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti TfR/Transferrin R (OX26) NB200-585 at a 1:100 dilution overnight at 4C and detected with an anti-mouse DyLight 488 (green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (red) at a 1:200 dilution. Nuclei were counterstained with DAPI (blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/TfR-Transferrin-R-Antibody-OX26-Immunocytochemistry-Immunofluorescence-NB200-585-img0007.jpg)
![Immunohistochemistry-Paraffin: TfR (Transferrin R) Antibody (OX26) [NB200-585] - Analysis of FFPE mouse spleen using TfR (OX26) antibody at 1:50 on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images was performed using Aperio AT2 (Leica Biosystems). Plasma membrane staining was observed. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/TfR-Transferrin-R-Antibody-OX26-Immunohistochemistry-Paraffin-NB200-585-img0012.jpg)
![Flow Cytometry: TfR (Transferrin R) Antibody (OX26) [NB200-585] - Analysis using the Biotin conjugate of NB200-585. Staining of mouse spleen.](http://images.novusbio.com/fullsize/TfR-Transferrin-R-Antibody-OX26-Flow-Cytometry-NB200-585-img0010.jpg)
![Flow Cytometry: TfR (Transferrin R) Antibody (OX26) [NB200-585] - Staining of rat spleen lymphocytes with mouse anti rat CD71.](http://images.novusbio.com/fullsize/TfR-Transferrin-R-Antibody-OX26-Flow-Cytometry-NB200-585-img0001.jpg)
![Flow (Intracellular): TfR (Transferrin R) Antibody (OX26) [NB200-585] - PC-12 cells were stained with NB200-585 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by DyLight488-conjugated anti-mouse secondary antibody.](http://images.novusbio.com/fullsize/TfR-Transferrin-R-Antibody-OX26-Flow-Intracellular-NB200-585-img0008.jpg)
![Flow Cytometry: TfR (Transferrin R) Antibody (OX26) [NB200-585] - Staining of rat spleen cells with mouse anti rat CD71: RPE.](http://images.novusbio.com/fullsize/TfR-Transferrin-R-Antibody-OX26-Flow-Cytometry-NB200-585-img0006.jpg)
![Flow Cytometry: TfR (Transferrin R) Antibody (OX26) [NB200-585] - An intracellular stain was performed on PC12 cells with TfR (Transferrin R) [OX26] Antibody NB200-585AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/TfR-Transferrin-R-Antibody-OX26-Flow-Cytometry-NB200-585-img0013.jpg)
![Western Blot: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Analysis of P65 using p65 antibody at 2 ug/mL in 30 ug of A) Ramos, B) Daudi, C) HeLa and D) mouse NIH 3T3 cell lysate.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Western-Blot-NB100-56712-img0013.jpg "Western Blot: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Analysis of P65 using p65 antibody at 2 ug/mL in 30 ug of A) Ramos, B) Daudi, C) HeLa and D) mouse NIH 3T3 cell lysate.")
![Simple Western: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Lane view shows a specific band for NFkB p65 in 1.0 mg/mL of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Simple-Western-NB100-56712-img0006.jpg)
![Western Blot: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Lysates of HeLa human cervical epithelial carcinoma cell line and Daudi human Burkitt's lymphoma cell line. PVDF membrane was probed with 1 ug/mL mouse anti-RelA/NFkB p65 monoclonal (NB100-56712, Novus Biologicals), followed by 1:2000 dilution of the appropriate HRP-conjugated secondary antibody, donkey anti-mouse IgG (HAF018).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Western-Blot-NB100-56712-img0016.jpg)
![Immunohistochemistry-Paraffin: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Ovarian cystadenocarcinoma probed with p65 antibody at 5 ug/mL. Human tissue TMA was used for this test. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM sodium citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Immunohistochemistry-Paraffin-NB100-56712-img0009.jpg)
![Flow Cytometry: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Intracellular staining of 293 HEK cells using 0.5 ug of p65 antibody. Green histogram represents the isotype control (p65) antibody. This NFkB p65 antibody was used for this test with an anti-mouse IgG PE conjugated secondary antibody.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Flow-Cytometry-NB100-56712-img0004.jpg)
![Simple Western: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Detection of p65 by Simple Western (JESS) in chemiluminescence in nuclear extract of reconstructed human epidermis lysate (about 600 ug/mL protein concentration).Antibody at 1:20. Simple Western image submitted by a verified customer review.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Simple-Western-NB100-56712-img0017.jpg)
![Western Blot: TfR (Transferrin R) Antibody [NB100-92243] - Analysis of TfR1 pAb at 1:500 dilution. (1) HEK293T whole cell lysate, (2) Raw264.7 whole cell lysate, and (3) H9C2 whole cell lysate.](http://images.novusbio.com/fullsize/TfR-Transferrin-R-Antibody-Western-Blot-NB100-92243-img0006.jpg "Western Blot: TfR (Transferrin R) Antibody [NB100-92243] - Analysis of TfR1 pAb at 1:500 dilution. (1) HEK293T whole cell lysate, (2) Raw264.7 whole cell lysate, and (3) H9C2 whole cell lysate.")
![Immunocytochemistry/Immunofluorescence: TfR (Transferrin R) Antibody [NB100-92243] - Transferrin Receptor Antibody [NB100-92243] - Transferrin receptor antibody was tested at 1:50 in HeLa cells with DylLght 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red). Image objective 40x.](http://images.novusbio.com/fullsize/Transferrin-Receptor-Antibody-Immunocytochemistry-Immunofluorescence-NB100-92243-img0004.jpg)
![Immunohistochemistry-Paraffin: TfR (Transferrin R) Antibody - BSA Free [NB100-92243] - Analysis of a FFPE tissue section of human placenta using 1:200 dilution of TfR (Transferrin R) antibody NB100-92243. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/TfR-Transferrin-R-Antibody-BSA-Free-Immunohistochemistry-Paraffin-NB100-92243-img0007.jpg)
![Western Blot: TfR (Transferrin R) Antibody [NB100-92243] - Analysis of Transferrin Receptor Antibody in extracts from 293 cells.](http://images.novusbio.com/fullsize/Transferrin-Receptor-Antibody-Western-Blot-NB100-92243-img0001.jpg)
![Immunohistochemistry-Paraffin: TfR (Transferrin R) Antibody [NB100-92243] - Paraffin-embedded human colorectal carcinoma tissue at 1:50.](http://images.novusbio.com/fullsize/TfR-Transferrin-R-Antibody-Immunohistochemistry-Paraffin-NB100-92243-img0005.jpg)
![Blocking/Neutralizing: RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - Effect of various p65-inhibitor peptides on binding of purified recombinant p65 protein to the DNA in vitro. Recombinant p65 protein (100 ng/sample) was incubated for 30 minutes with 50uM of various peptides in 0.025 ml and then assayed for DNA binding activity by EMSA (Please refer to Takada et al, 2004 for further details).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Inhibitor-Peptide-Set-Blocking-Neutralizing-NBP2-26505-img0008.jpg "Blocking/Neutralizing: RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - Effect of various p65-inhibitor peptides on binding of purified recombinant p65 protein to the DNA in vitro. Recombinant p65 protein (100 ng/sample) was incubated for 30 minutes with 50uM of various peptides in 0.025 ml and then assayed for DNA binding activity by EMSA (Please refer to Takada et al, 2004 for further details).")
![Blocking/Neutralizing: RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - PTD-p65-P1 peptide inhibits TNF-induced NF-kB activation: KBM-5 cells were incubated with various concentrations of peptides for 1 hr and treated with 0.1nM TNF for 30 min. Nuclear extracts were prepared and NF-kB activation was analyzed by EMSA (Please refer to Takada et al, 2004 for further details).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Inhibitor-Peptide-Set-Blocking-Neutralizing-NBP2-26505-img0009.jpg)
![Functional (Inhibition): RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - TLR5/NF-kB/SEAPorter HEK 293 (NBP2-26277) cells were plated in 96-well plates at 5 x 10^4 cells/well for 16 h. Cells were preincubated with different concentrations (0, 1, 5, 10, 25 and 50 uM) of Inhibitory Peptide (NBP2-26505) and Control Peptide (NBP2-29334) for 1 h. Cells were then stimulated with 1 ng/ml Flagellin (NBP2-25289) for 24 h. Secreted alkaline phosphatase (SEAP) was analyzed using SEAPorter Assay Kit (NBP2-25285). *p < 0.05 versus control peptide at the corresponding concentrations (Mann-Whitney U test).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-p-Ser276-Inhibitor-Peptide-Set-Functional-Inhibition-NBP2-26505-img0010.jpg)